NCT02798406: A trial that was reported late by DNAtrix, Inc.
This trial has reported, although it was 118 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02798406 |
|---|---|
| Title | A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 6, 2016 |
| Completion date | March 17, 2021 |
| Required reporting date | March 17, 2022, midnight |
| Actual reporting date | July 13, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 118 |